Proprotein convertase subtilisin/kexin type 9 (PCSK9) has evolved as a pivotal enzyme in
lipid metabolism and a revolutionary therapeutic target for hypercholesterolemia and its …

SILAC is based on direct addition of selected stable isotope amino acids into the cell culture
medium, allowing superior quantitative analysis of the cellular proteome compared to other …

Background Cancer is emerging as a major problem globally, as it accounts for the second
cause of death despite medical advances. According to epidemiological and basic studies …

Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes degradation of low-density
lipoprotein receptor (LDLR) and plays a central role in regulating plasma levels of LDL …

Clinical trials have unequivocally shown that inhibition of proprotein convertase
subtilisin/kexin type 9 (PCSK9) efficaciously and safely prevents cardiovascular events by …

Gastric cancer (GC) is a highly malignant disease affecting humans worldwide and has a
poor prognosis. Most GC cases are detected at advanced stages due to the cancer lacking …

Cholesterol is crucial for cell survival and growth, and dysregulation of cholesterol
homeostasis has been linked to the development of cancer. The tumor microenvironment …

Cancer is a disease with a significant global burden in terms of premature mortality, loss of
productivity, healthcare expenditures, and impact on mental health. Recent decades have …

Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a novel
pharmacological target for hypercholesterolemia and associated cardiovascular diseases …

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is the last discovered member of the
family of proprotein convertases (PCs), mainly synthetized in hepatic cells. This serine …